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Abstract:  
Purpose: Pulmonary hypertension and exercise-induced oxygen desaturation (EID) influence 
acute exacerbation of chronic obstructive pulmonary disease (COPD). Computed tomography 
(CT)-detected pulmonary artery (PA) enlargement is independently associated with acute COPD 
exacerbations. Associations between PA to aorta (PA:A) ratio and EID in patients with COPD 
have not been reported. We hypothesised that the PA:A ratio correlated with EID and results of 
the 6-min walk test (6MWT) would be useful for predicting the risk associated with PA:A > 1. 
Patients and methods: We retrospectively measured lung function, 6MWT, emphysema area, 
and PA enlargement on CT in 64 patients with COPD. The patients were classified into groups 
with PA:A ratio ≤ 1 and > 1. Receiver-operating characteristic (ROC) curves were used to 
determine the threshold values with the best cutoff points to predict patients with PA:A > 1. 
Results: The PA:A > 1 group had lower forced expiratory volume in 1 second (FEV1), forced 
vital capacity (FVC), FEV1:FVC ratio, diffusion capacity of lung carbon monoxide (DLCO), 6-
min walk distance (6MWD) and baseline peripheral oxygen saturation (SpO2), lowest SpO2, 
highest modified Borg Scale results, percentage low-attenuation are (LAA%), and history of 
acute COPD exacerbations ≤ 1 year and worse BODE (Body mass index, airflow Obstruction, 
Dyspnea, and Exercise) index results (p < 0.05). Predicted PA:A >1 was determined for SpO2 
during 6MWT (best cutoff point: 89%, area under the curve [AUC] 0.94, 95% confidence 
interval 0.88–1). SpO2 < 90% during 6MWT showed a sensitivity of 93.1, specificity of 94.3, 
positive predictive values of 93.1, negative predictive values of 94.3, positive likelihood ratios of 
16.2, and negative likelihood ratios of 0.07. 
Conclusion: Lowest SpO2 during 6MWT may predict CT-measured PA:A ratios, and lowest 
SpO2 <89% during 6MWT is excellent for detecting pulmonary hypertension in COPD. 
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Introduction 
Exacerbations of chronic obstructive pulmonary disease (COPD) are associated with accelerated 
loss of lung function, poor quality of life and mortality.1,2 These events can be predicted by 
numerous clinical factors, including prior exacerbations, airflow obstruction, symptom burden, 
gastroesophageal reflux, and leukocytosis.3 It is important to detect COPD exacerbations early 
and minimise their severity.  
     Patients with COPD frequently experience significant decreases in oxygen saturation during 
exercise attributed to the imbalance between oxygen delivery and exercise-induced demand.4 
Exercise-induced oxygen desaturation (EID) is reported to be associated with hospitalisation and 
mortality in patients with COPD.5 The 6-min walking test (6MWT) has been suggested as the 
preferred measure to identify patients with COPD and EID.6 EID occurs frequently during 
6MWT in patients with COPD.7 EID has been related to forced expiratory volume in 1 s (FEV1), 
diffusion capacity of lung carbon monoxide (DLCO), amount of emphysema and baseline oxygen 
saturation.8–10 
     Pulmonary hypertension (PH) is an important factor contributing to acute exacerbation of 
COPD.11 PH appears when airflow limitation is severe, and is associated with chronic hypoxemia. 
Pulmonary vascular remodelling in COPD is the main cause of increased pulmonary artery (PA) 
pressure, and is thought to result from the combined effects of hypoxia, inflammation and 
capillary loss in severe emphysema.12 The presence of PH has been shown to increase the 
hospitalisation rate and mortality of patients with COPD.13,14 Computed tomography (CT)-
detected PA enlargement is independently associated with acute exacerbations of COPD.15 The 
PA-to-aorta (PA:A) ratio measured by CT scan outperforms echocardiography for diagnosing 
resting PH in patients with severe COPD.16 A PA:A >1 indicates lower oxygen saturation at rest 
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than a PA:A <1.15 However, there are no reports on the association between PA:A and EID in 
patients with COPD. 
     We hypothesised that the PA:A correlates with the presence of EID and that 6MWT results are 
useful for predicting the risk of having a PA:A >1. The present study aimed to examine the 
relationship between PA:A and EID and develop a simple screening tool by determining the 
appropriate cut-off score on 6MWT to predict a PA:A >1 in patients with COPD. 
 
Patients and methods 
Study design and patient selection 
This study analysed regularly treated outpatients with COPD between 2014 and 2015 at the Kobe 
City Medical Center West Hospital. A total of 64 patients with COPD were included after 
applying the exclusion criteria in this study (Figure 1). The criteria for diagnosing COPD were a 
smoking history (≥20 pack-years) and post-bronchodilator FEV1/forced vital capacity (FVC) < 
70%. Furthermore, we used the following inclusion criteria to define COPD clinically, all of 
which had to be fulfilled: symptoms, including cough, sputum production, wheezing, dyspnea, a 
smoking history (≥20 pack-years), existence of emphysema on chest CT, and a physician 
diagnosis of COPD.17–21 Study-exclusion criteria were as follows: history of lung surgical 
procedures, exacerbation-related hospitalization 3 months before 6MWT, and patients on long-
term oxygen therapy. This study was approved by the ethics committee of Kobe University 
(N287). All the participants provided written or oral informed consent. 
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Figure 1 Patients flow diagram 
Abbreviations: PA, pulmonary artery; A, aorta. 
 
Clinical Characterisation 
Assessments 
A chest physician performed the physical examination for all outpatients. This examination 
included an assessment of body weight, height, and medical history (eg, pulmonary embolism 
and sleep apnea syndrome), GOLD (Global Initiative for Obstructive Lung Disease) grade 0–4, 
history of acute exacerbations of COPD within the previous year, COPD Assessment Test (CAT), 
level of dyspnea (using the modified Medical Research Council [mMRC] dyspnoea scale), post-
bronchodilator spirometry, DLCO, 6MWT (according to international recommendations), 
emphysema area, and PA enlargement on CT. Body mass index (BMI) was calculated as weight 
in kilograms divided by height in meters squared. GOLD 0 was defined as current and former 
smokers with a normal post-bronchodilator ratio of FEV1: FVC exceeding 0.7 and an FEV1 of at 
least 80%, symptoms, including cough, sputum production, wheezing and dyspnea, smoking 
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history (≥20 pack-years), existence of emphysema on chest CT, and a physician diagnosis of 
COPD.17–21 
 
Six-minute walk test 
The 6MWT was performed according to the 2002 American Thoracic Society guidelines.22 
Participants were asked to walk indoors on a flat, round, 25 m walking course supervised by a 
physician and physical therapist. A practice 6MWT was not undertaken. Subjects were 
encouraged using standard methodology every minute of the 6MWT. A pulse oximeter (WristOx 
3150; Nonin Medical, Plymouth, MN, USA) with a finger probe measured peripheral oxygen 
saturation (SpO2) during 6MWT, and 6MWT-analysis software (WristOx 2; Star Product, Tokyo, 
Japan) was used. In addition, a modified Borg scale was used to quantify the levels of dyspnea 
perceived by subjects at each minute during 6MWT. EID was defined as a nadir SpO2 <90%, 
SpO2 ≤88% and ΔSpO2 ≥4%.23–25 
 
Measuring the PA:A ratio 
One reviewer, blinded to hemodynamic information, analysed CT scans (Optima CT 660 
Discovery; GE Healthcare, Little Chalfont, UK). Measurements of the diameter of the main PA 
and the diameter of the aorta (A) at the level of the bifurcation were used to calculate the PA:A 
ratio, as previously reported.14–16 In cases where the aorta was not uniform in diameter, two 
measurements were taken 90° apart and the larger diameter used. PA was measured on the line 
that joins the origin of the left PA and the centre of the adjacent ascending aorta on the axial 
section at the level of PA bifurcation.26 CT-measured relative PA enlargement was defined as 
PA:A >1 (Figure 2).14–16 
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Figure 2. Measurement of the PA and A diameters at the PA bifurcation. 
Notes: (A) PA:A ≤1, (B) PA:A >1. The κ-values for intraobserver and interobserver agreements for detecting PA:A >1 were 0.87 (95% confidence interval 0.74–
0.99) and 0.75 (95% confidence interval 0.58–0.91), respectively. 
Abbreviations: PA, pulmonary artery; A, aorta. 
 
Statistical Analysis 
Results are expressed as counts or median (interquartile range). Data are presented as means and 
standard deviations or as proportions, as appropriate. Cohen’s κ-coefficient measured 
intraobserver and interobserver agreements for CT measurements of the PA:A ratio. Bivariate 
analyses were performed with the use of a Pearson’s χ2 test for categorical data and Mann–
Whitney U-test for continuous data when appropriate. The Spearman’s rank-correlation 
coefficient was determined for relationships between the PA:A ratio, lung function parameters, 
6MWT parameters, and CT parameters. Receiver operating characteristic (ROC) curves were 
used to determine the threshold values with the best sensitivity and specificity to predict PA:A > 
1, with the best being defined as the point on the ROC curve with the shortest distance from the 
upper-left corner. Sensitivity, specificity, positive/negative predictive value (PPV/NPV), and 
positive/negative likelihood were calculated for lung-function parameters and 6MWT parameters 
of exacerbation-risk factors on the basis of a previous study.6,27,28  
(a)	 (b)	
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     All statistical analyses were performed with EZR (Saitama Medical Center, Jichi Medical 
University, Saitama, Japan), which is a graphical user interface for the R project (R Foundation 
for Statistical Computing, Vienna, Austria).29 More precisely, it is a modified version of R 
Commander designed to add statistical functions frequently used in biostatistics, and P-values 
<0.05 were considered statistically significant. 
 
Results 
The current analysis comprised 64 patients who were separated into groups on the basis of PA:A  
>1 (n = 29) and ≤1 (n = 35). Participants had a mean age of 73 (68–79) years. Fifty were male 
(78.1%) and 14 were female (21.9%). The κ-values for intraobserver and interobserver 
agreements for detecting PA:A >1 were 0.87 (95% confidence interval [CI] 0.74–0.99) and 0.75 
(95% CI 0.58–0.91), respectively. 
     Differences in the PA:A ratio between both groups were driven by the diameter of PA (2.9 
[2.7–3.3] cm in PA:A ≤ 1 vs. 3.7 [3.5–3.9] cm in PA:A >1, P= 0.002), because no differences 
were detected in the diameter of aortae (3.7 [3.4–3.9] cm vs. 3.5 [3.3–3.7] cm, P= 0.20). There 
were no significant differences between the two groups with regard to age, sex, BMI, pack-years, 
mMRC dyspnea scale, GOLD, COPD assessment test, baseline pulse rate, baseline modified 
Borg Scale (P> 0.05). On the other hand, there were significant differences between the two 
groups with regard to FEV1 (71.6% [60.5%–80.8%] vs. 52.6% [39.6%–72.1%], P= 0.013), FVC 
(82.3% [50.3%–93.6%] vs. 75.8% [42.7%–86.0%], P= 0.04), FEV1:FVC ratio (68% [61%–
73.3%] vs. 53.8% [48.8%–69.4%], P= 0.023), %DLCO (72.5% [55.5%–82.9%] vs. 44.6% 
[37.7%–49.6%], P= 0.005), BODE (BMI, obstruction [airflow], dyspnea, and exercise 
performance) index (2 [1–3] vs. 4 [2–5], P< 0.001), 6-min walking distance (6MWD; 450 m 
 6MWT as a Screening Test for PAE in COPD  
 
 8 
[400–510.5] vs. 325 m [238–466], P< 0.001), baseline SpO2 (97% [95%–97.5%] vs. 95% [93%–
96%], P= 0.001), lowest SpO2 (92% [91%–94%] vs. 86% [84%–88%], P< 0.001), highest 
modified Borg Scale result (2 [0–5] vs. 5 [2–5], P= 0.04), low-attenuation area (LAA; 6.8% 
[2.8%–14.7%] vs. 25.4% [11.3%–33.4%], P< 0.001), and history of acute exacerbations of 
COPD within the previous year (1 [2.9%] vs. 7 [24.1%], P= 0.019) (Table 1). 
     The PA:A ratio demonstrated a significant linear correlation with lowest SpO2 (r= −0.68, r2= 
0.46; P< 0.001), %DLCO (r= −0.61, r2= 0.37; P< 0.001), 6MWD (r= −0.43, r2= 0.18; P< 0.001), 
BODE index (r= 0.41, r2= 0.17; P< 0.001), baseline SpO2 (r= −0.36, r2= 0.13; P= 0.003), LAA% 
(r= 0.36, r2= 0.13; P= 0.004), FVC (r= −0.34, r2= 0.12; P= 0.006), FEV1 (r= −0.29, r2= 0.08; P= 
0.019) and highest pulse rate (r= 0.26, r2= 0.07; P= 0.035) (Table 2).  
     Using ROC curves, the threshold values with the best cutoff point, sensitivity, and specificity 
to predict PA:A >1 were determined for SpO2 during 6MWT (best cutoff points 89%, area under 
curve [AUC] 0.94, 95%CI 0.88–1), DLCO (best cutoff points 51%, AUC 0.87, 95%CI 0.78–0.96), 
6MWD (best cutoff points 388m, AUC 0.75, 95%CI 0.62–0.87), BODE index (best cutoff points 
4, AUC 0.74, 95%CI 0.61–0.87) (Table 3, Figure 3). The performance data on the 6MWT and 
lung function for predicting PA enlargement are depicted in Table 4. SpO2 < 90%, SpO2 ≤ 88%, 
and ΔSpO2 ≥4% during 6MWT were 94.3 (80.8–99.3), 97.1 (85.1–99.9), and 45.7 (28.8–63.4), 
respectively, for specificity, 93.1 (77.2–99.2), 95.8 (78.9–99.9) and 59.6 (44.3–73.6), respectively, 
for positive predictive value, and 16.2 (4.2–62.8), 27.7 (4–193.3), and 1.8 (1.3–2.4), respectively, 
for positive likelihood ratios.  
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Table 1  General characteristics of the patients with PA:A ≤1 and PA:A >1 
Variable PA:A ≤1 (n=35) PA:A >1 (n=29) P-value 
Age (years) 71 (66.5–76.5) 78 (70–79) 0.06b 
Male sex (%) 28 (80) 22 (75.9) 0.76a 
Body mass index (kg/m2) 21.1 (19.5–23.4) 22.4 (20.4–24.7) 0.33b 
Smoking history (pack-years) 40 (26.8–60) 40 (35–50) 0.49b 
PE 0 1 (3.4%) 0.45a 
SAS 1 (2.8%) 0 1a 
GOLD (0/1/2/3/4) 14/3/13/4/1 7/2/8/11/1 0.14a 
mMRC (0/1/2/3/4) 1/7/22/5/0 0/2/21/5/1 0.36a 
COPD Assessment Test (points) 15 (8–22) 14 (11.5–22) 0.62b 
BODEindex (points) 2 (1–3) 4 (2–5) <0.001b 
FEV1 (% of predicted value) 71.6 (60.5–80.8) 52.6 (39.6–72.1) 0.013b 
FVC (% of predicted value) 82.3 (50.3–93.6) 75.8 (42.7–86) 0.04b 
FEV1:FVC ratio 68 (61–73.3) 53.8 (48.8–69.4) 0.023b 
DLCO (% of predicted value) 72.5 (55.5–82.9) 44.6 (37.7–49.6) 0.005b 
RV/TLC (%) 43.7 (37.4–48.6) 48.8 (39.8–53.8) 0.12b 
LAA (%) 6.8 (2.8–14.7) 25.4 (11.3–33.4) <0.001b 
Admission for exacerbation 1 (2.9) 7 (24.1) 0.019a 
6MWD (m) 450 (400–510.5) 325 (238–446) <0.001b 
Baseline SpO2 (%) 97 (95–97.5) 95 (93–96) 0.001b 
Lowest SpO2 (%) 92 (91–94) 86 (84–88) <0.001b 
Baseline PR (bpm) 74 (69.5–81.5) 77 (70–88) 0.28b 
Highest PR (bpm) 108 (98–115.5) 112 (108–120) 0.014b 
Baseline modified Borg Scale 0 (0–0) 0 (0–0.5) 0.1b 
Highest modified Borg Scale 2 (0–5) 5 (2–5) 0.04b 
Diameter of aorta (cm) 3.7 (3.4–3.9) 3.5 (3.3–3.7) 0.2b 
Diameter of pulmonary artery (cm) 2.9 (2.7–3.3) 3.7 (3.5–3.9) 0.002b 
Notes: Data presented as counts (%) or median (interquartile range). P-values calculated by aPearson’s χ2 test (categorical) and bMann–Whitney U-test (continuous). 
Abbreviations: PA, pulmonary artery; A, aorta; PE, pulmonary embolism; SAS, sleep apnoea syndrome; GOLD, Global Initiative for Obstructive Lung Disease; 
mMRC, modified Medical Research Council; CAT, COPD Assessment Test; BODE, body mass index, airflow obstruction, dyspnoea and exercise; FEV1, forced 
expiratory volume in 1 second; FVC, forced vital capacity; DLCO, diffusion capacity of lung carbon monoxide; RV/TLC, residual volume/total lung capacity; LAA%, 
the percentage of the lung field occupied by low attenuation areas; 6MWD, 6-minute walking distance; Baseline SpO2, resting SpO2 before 6MWT; Lowest SpO2, 
nadir SpO2 during the 6MWT; Baseline PR, resting pulse rate before 6MWT; highest PR, Highest value of pulse rate during 6MWT; Baseline modified Borg Scale, 
resting modified Borg Scale before 6MWT; Highest modified Borg Scale, highest value of modified Borg Scale during 6MWT  
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Table 2  Linear relationships between PA:A ratio, lung function, and index of 6MWT 
Variable r r2 P-valuea 
Lowest SpO2 (%) -0.68 0.46 <0.001 
DLCO (% of predicted value) -0.61 0.37 <0.001 
6MWD (m) -0.43 0.18 <0.001 
BODE index 0.41 0.17 <0.001 
Baseline SpO2 (%) -0.36 0.13 0.003 
LAA (%) 0.36 0.13 0.004 
FVC (% of predicted value) -0.34 0.12 0.006 
FEV1 (% of predicted value) -0.29 0.08 0.019 
Highest PR (bpm) 0.26 0.07 0.035 
Notes: aP-value calculated by Spearman’s rank-correlation coefficient. 
Abbreviations: PA, pulmonary artery; A, aorta; 6MWT, 6-minute walking test; Lowest SpO2, nadir SpO2 during the 6MWT; DLCO, diffusion capacity of the 
lung carbon monoxide; 6MWD, 6-min walking distance; BODE index, body mass index, obstruction (airflow), dyspnoea and exercise; Baseline SpO2, resting SpO2 
before 6MWT; LAA, low-attenuation areas; FVC, forced vital capacity; FEV1, forced expiratory volume in 1 s; Highest PR, highest value of pulse rate during 6MWT 
 
Table 3 Cut off points and ROC-curve parameters for the prediction of PA:A ratio > 1 
Variable Best cutoff AUC (95% CI) Sensitivity Specificity 
Lowest SpO2 (%) 89 0.94 (0.88–1) 86.2 93.1 
DLCO  (%) 51 0.87 (0.78–0.96) 79.3 85.7 
6MWD (m) 388 0.75 (0.62–0.87) 69 80 
BODE index (points) 4 0.74 (0.61–0.87) 58.6 85.7 
Abbreviations: ROC, receiver-operating characteristic; PA, pulmonary artery; A, aorta; AUC, area under the curve; Lowest SpO2, nadir SpO2 during the 6MWT; 
DLCO, diffusion capacity of lung carbon monoxide; 6MWD, 6-minute walking distance; BODE index, body mass index, obstruction (airflow), dyspnoea and exercise; 
CI, confidence interval. 
 
 
Figure 3 Receiver operator characteristic curve with lowest SpO2 during 6MWT identifying PA:A ratio > 1  
Abbreviations: lowest SpO2, nadir SpO2 during the 6MWT; 6MWT, 6-min walking test; PA, pulmonary artery; A, aorta; AUC, area under the curve. 
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Table 4 The performance data of 6MWT and lung function for PA:A ratio > 1 
Abbreviations: PPV, positive predictive values; NPV, negative predictive values; +LR, positive likelihood; −LR, negative likelihood; 6MWT, 6-min walking test; Baseline 
SpO2, resting SpO2 before 6MWT; 6MWD, 6-min walking distance; FEV1, forced expiratory volume in 1 s; DLCO, diffusion capacity of the lung carbon monoxide 
 
Discussion 
We were able to reveal three main findings in the present study. First, we found a strong 
association between PA:A ratio and lowest SpO2 during 6MWT. For this reason, a consistent 
finding in patients with COPD is the close relationship between severity of hypoxemia and PA 
pressure or pulmonary vascular resistance, supporting a major role for alveolar hypoxia.30 
Alveolar hypoxia causes constriction of the resistance PAs, and sustained alveolar hypoxia 
induces pulmonary vascular remodelling.28 Pathological studies of lung specimens from patients 
with COPD have shown extensive pulmonary vascular remodelling with prominent intimal 
thickening and medial hypertrophy. For this reason, chronic alveolar hypoxia plays an important 
role in pulmonary vascular remodelling.28 In a previous study, patients with PA:A >1 showed 
lower resting SpO2, higher usage rates of supplemental oxygen, and an indirect association with 
EID.15 In the present study, the lowest SpO2 during 6MWT to predict PA:A > 1 was considered 
to be a beneficial result based on the ROC curves. Lowest SpO2 < 89% during the 6MWT is 
excellent in the detection of PH. These results suggest that the lowest SpO2 during 6MWT is a 
Variable 
Sensitivity 
 (95% CI) 
Specificity  
(95% CI) 
PPV  
(95% CI) 
NPV  
(95% CI) 
+LR 
(95% CI) 
-LR  
(95% CI) 
SpO2 <90% 93.1 (77.2–99.2) 94.3 (80.8-99.3) 93.1 (77.2-99.2) 94.3 (80.8-99.3) 16.2 (4.2-62.8) 0.07 (0.02-0.28) 
SpO2 ≤88% 79.3 (60.3-92) 97.1 (85.1-99.9) 95.8 (78.9–99.9) 85 (70.2–94.3) 27.7(4–193.3) 0.21(0.1–0.44) 
ΔSpO2 ≥4% 96.6 (82.0–99.9) 45.7 (28.8–63.4) 59.6 (44.3–73.6) 94.1 (71.3–99.9) 1.8 (1.3–2.4) 0.08 (0.01–0.54) 
Baseline SpO2 ≤95% 58.6 (38.9–76.5) 71.4 (53.7–85.4) 63.0 (42.4–80.6) 67.6 (50.2–82.0) 2.1 (1.1–3.8) 0.58 (0.36–0.94) 
6MWD <350 m 58.6 (38.9–76.5) 82.9 (66.4–93.4) 73.9 (51.6–89.8) 70.7 (54.5–83.9) 3.4 (1.6–7.5) 0.50 (0.32–0.80) 
SpO2 <90% and 6MWD <350m 51.7 (32.5–70.6) 97.1 (85.1–99.9) 93.8 (69.8–99.8) 70.8 (55.9–83.0) 18.1 (2.5–128.9) 0.50 (0.34–0.73) 
SpO2 ≤88% and 6MWD <350m 51.7 (32.5–70.6) 100 (85.5–100) 100 (69.8–100) 71.4 (56.7–83.4) - 0.48 (0.33–0.70) 
ΔSpO2 ≥4% and 6MWD <350m 55.2 (35.7–73.6) 91.4 (76.9–98.2) 84.2 (60.4–96.6) 71.1 (55.7–83.6) 6.4 (2.1–19.9) 0.49 (0.32–0.74) 
FEV1 <80% 79.3 (60.3–92.0) 31.4 (16.9–49.3) 48.9 (34.1–63.9) 64.7 (38.3–85.8) 1.2 (0.9–1.5) 0.65 (0.28–1.56) 
FEV1 <50% 44.8 (26.4–64.3) 85.7 (69.7–95.2) 72.2 (46.5–90.3) 65.2 (49.8–78.6) 3.1 (1.3–7.8) 0.64 (0.45–0.92) 
DLCO <50% 75.9 (56.5–89.7) 85.7 (69.7–95.2) 81.5 (61.9–93.7) 81.1 (64.8–92.0) 5.3 (2.3–12.3) 0.28 (0.15–0.54) 
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very helpful measure and screening test for PA:A ratio. For example, it might be possible to 
easily screen for pulmonary artery expansion by means of the 6MWT in home-care situation, 
where it would be difficult to perform CT imaging. 
     Second, with regard to the relationship between PA:A ratio and lung function, correlations 
were observed among FEV1, DLCO, and LAA. One of the factors that may play a role in causing 
PH to advance in patients with COPD is the destruction of lung parenchyma, leading to loss of 
part of the pulmonary vascular bed,30,31 and the burden of airway remodelling influencing PA-
pressure increase.28 A previous study included patients with airflow-obstruction severity greater 
than moderate, and our study included mild airflow obstruction and smokers with normal 
spirometry.15 Therefore, regardless of the severity of airflow-obstruction, PA enlargement may be 
progressing. Undiagnosed COPD is a problem worldwide.18 GOLD 0 has been reported to be an 
exacerbation risk; therefore,18 early detection and not just spirometry evaluation is important 
from multiple perspectives.18,32 From the viewpoint of early detection of PA enlargement, a 
definition of EID as SpO2 <90% may be a good start. 
     Third, there are many causes for acute COPD exacerbations. However, these findings may 
imply that PA:A >1 is one of the multiple risk factors for acute COPD exacerbations. One reason 
for this is that PA:A is associated with PH16 and PH is also a risk factor for acute COPD 
exacerbations.33 Furthermore, a previous study reported an association between the PA:A ratio 
and acute COPD exacerbation.15 These results suggest that screening for the PA:A ratio without 
CT using the 6MWT may indicate the risk for acute COPD exacerbations at an early stage. 
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Limitation 
This study had some limitations, including small size, single-center experience, and retrospective 
design. In addition, this study also included COPD subjects who did not fit the GOLD criteria. 
Furthermore, because healthy controls do not have respiratory symptoms and there are no control 
data for the measurement items pertaining to such individuals, healthy controls were not included 
in the present study. However, it has been reported that the presence of clinical symptoms and 
low DLCO in smokers, even with normal spirometry, increases the risk of progression to airflow 
obstruction in COPD.17–20 Therefore, the present study’s results during the 6MWT could be 
useful to screen for PH at an early COPD stage, even in GOLD 0 patients. Finally, according to a 
previous study, left ventricular dysfunction causes PA enlargement. However, echocardiography 
was not performed in all subjects, and this information could not be included because it was 
unavailable from the medical history, although we observed clinically relevant associations 
between CT-measured PA:A ratios and 6MWT results. 
 
Conclusion 
The current study’s findings suggest that there is a strong association between PA:A ratio and 
lowest SpO2 during 6MWT. 6MWT is a simple, noninvasive, and reproducible measurement tool. 
Lowest SpO2 during 6MWT is a very helpful measurement to predict PA:A ratio on CT, and 
lowest SpO2 <89% during the 6MWT is excellent to screen for PH in COPD. 
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